

Disclosure regarding Eohilia[™] – The first FDA approved oral treatment for Eosinophilic Esophagitis (EoE).

Dear Patient:

The purpose of this disclosure is to inform you of the personal financial interests of Dr. Ranjan Dohil and Dr. Seema Aceves in Eohilia, one of the treatment options that may be prescribed to you at the Eosinophilic Disorders Clinic at Rady Children's Hospital-San Diego.

This information is being provided to you to ensure that you have all information necessary to make an informed decision about your healthcare, including information about alternative treatment options that may be available to you.

I: Eohilia Development

Dr. Dohil and Dr. Aceves have managed and overseen the Eosinophilic Gastrointestinal Disorders Clinic for more than twenty years. Most patients receiving care at this clinic have a condition called Eosinophilic Esophagitis, a lifelong esophageal allergic condition which, without effective treatment, can lead to scarring/narrowing of the esophagus and long-term problems with swallowing.

As you may know, Dr. Dohil and Dr. Aceves are leading researchers in their field and developed a treatment for patients with EoE. The treatment includes a topical steroid, specifically, oral viscous budesonide (OVB), which is a mixture of budesonide nebulizer solution (used for asthma) and a maltodextrin based muco-adherent agent. This medication has a very good safety record and is effective in the majority of patients. Over the last fifteen years, OVB has become standard of care therapy for EoE in the United States.

Takeda Pharmaceuticals has licensed OVB through The University of California, San Diego (UCSD) and has helped to develop and now commercialize the new OVB therapy, *EohiliaTM*. Although the composition of *EohiliaTM* is based on OVB it only contains natural products and does not contain any artificial sweeteners. *EohiliaTM* is the first Food and Drug Administration (FDA) approved oral treatment specifically for EoE. Dr. Dohil and Dr. Aceves research contributed to FDA approval of this medication. Due to their contribution to this scientific research, Dr. Dohil and Dr. Aceves will receive a small portion of the revenue from *EohiliaTM* in the form of a royalty payment through UC San Diego.

II: Treatment Options

Your doctor may recommend *EohiliaTM* if it is the most appropriate medication to treat your EOE. Medication options will be offered based solely on what is best for the individual patient, not on the providers' financial interest in the product.

There are several alternatives to **Eohilia**TM including:

- A "mix-at-home" formulation of OVB which is prescribed using off-label medication of nebulized budesonide.
- An injectable biologic (non-steroid), Dupiliumab, which is also an FDA approved treatment for EoE.
- Adhere to strict dietary restrictions, which may be effective in controlling EoE symptoms.

Your provider will make treatment/medication recommendations based on what they believe will be most effective for you. If you have any concerns about the recommended treatment, you should discuss these with your

provider. If your provider recommends Eohilia, you have a right to refuse the recommendation. You will not be treated any differently by your provider or the clinic if you choose to pursue a treatment other than Eohilia.

If you have any questions about this notice or Eohilia, please do not hesitate to speak with your provider. If you are not comfortable discussing this notice directly with your provider, you may also contact the Rady Children's Hospital Compliance Department at (858) 966-8541.

III: Patient Acknowledgment			
By signing this disclosure, you acknowledge that you have reunderstand that your physician has a financial interest in the	_		
Signature Parent / Patient (if over 18 years old)	Date / Time	Witness	
Relationship to Patient ID Required (if over 18 years old)	Area Code	Area Code & Phone Number	